The clinical application of atorvastatin in patients with small-cell lung cancer with dyslipidemia
ConclusionAtorvastatin added to first-line standard chemotherapy achieved prospective efficacy and manageable safety in SCLC combined dyslipidemia.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Atorvastatin Calcium | Cancer | Cancer & Oncology | Chemotherapy | China Health | Lipitor | Lung Cancer | Small Cell Lung Cancer | Statin Therapy | Study | Teaching | Teaching Hospitals | Toxicology | Universities & Medical Training | Zivast